The hypercoagulability treatment market is projected to grow from USD 767.1 million in 2025 to USD 1,509.0 million by 2035, at a CAGR of 7.0%. Heparin will dominate with a 48.6% market share, while oral will lead the route of administration segment with a 55.2% share.